Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 5:54 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Nebivolol Clear all
Completed Phase 4 Interventional Results available

Nebivolol Effect on Nitric Oxide Levels, Blood Pressure, and Renal Function in Kidney Transplant Patients

NCT01157234
View directory record Official record
Conditions
Hypertension
Interventions
Nebivolol, Metoprolol
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Nov 5, 2024 · Synced Sep 24, 2026, 5:54 PM EDT
Terminated Phase 4 Interventional Results available

Alternative in Beta Blocker Intolerance: The ABBI Trial

NCT00893984
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Nebivolol
Drug
Lead sponsor
Minneapolis Heart Institute Foundation
Other
Eligibility
21 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 5, 2019 · Synced Sep 24, 2026, 5:54 PM EDT
Not listed No phase listed Observational

Economic Impact of Switching From Metoprolol to Nebivolol for Hypertension Treatment

NCT01758263
View directory record Official record
Conditions
Hypertension
Interventions
Metoprolol, Nebivolol
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Jersey City, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 31, 2012 · Synced Sep 24, 2026, 5:54 PM EDT
Completed Phase 4 Interventional Results available

Study of the Glycemic Effects of Nebivolol Compared With Metoprolol and HCTZ in Diabetic Hypertensive Patients

NCT00744237
View directory record Official record
Conditions
Hypertension, Type 2 Diabetes Mellitus
Interventions
Nebivolol, Metoprolol ER, HCTZ
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 85 Years
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
62
States / cities
Athens, Alabama • Huntsville, Alabama • Bell Gardens, California + 54 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2011 · Synced Sep 24, 2026, 5:54 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Efficacy and Safety of Valsartan and Nebivolol/Valsartan in Hypertensive Patients With LVH

NCT03180593
View directory record Official record
Conditions
Hypertension Complicated, Hypertrophy, Left Ventricular, Blood Pressure
Interventions
Valsartan 80 mg
Drug
Lead sponsor
Trinity Hypertension & Metabolic Research Institute
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Carrollton, Texas
Source: ClinicalTrials.gov public record
Updated Apr 10, 2018 · Synced Sep 24, 2026, 5:54 PM EDT
Completed Phase 4 Interventional Results available

Pilot Deprescribing N-of-1 Trials for Beta-blockers in HFpEF

NCT04757584
View directory record Official record
Conditions
Heart Failure, Heart Failure, Diastolic, Heart Failure With Preserved Ejection Fraction, Cardiac Failure, Heart Disease
Interventions
Beta blockers
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
65 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 8, 2024 · Synced Sep 24, 2026, 5:54 PM EDT
Completed Phase 4 Interventional Results available

Comparison of Nebivolol and Metoprolol With Exercise and Angiotensin II in Hypertensive Patients

NCT01502787
View directory record Official record
Conditions
Hypertension
Interventions
Metoprolol succinate, Nebivolol, Forearm blood flow, Microneurography, Rhythmic handgrip exercise, Lower body negative pressure, Angiotensin II
Drug · Procedure
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 6, 2020 · Synced Sep 24, 2026, 5:54 PM EDT
Completed Phase 3 Interventional

Dosing Study of the Effects of Nebivolol on Blood Pressure in Black Patients With Mild to Moderate Hypertension

NCT00145236
View directory record Official record
Conditions
Hypertension
Interventions
Nebivolol
Drug
Lead sponsor
Mylan Bertek Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Sep 13, 2005 · Synced Sep 24, 2026, 5:54 PM EDT
Completed Phase 4 Interventional Results available

A Study on the Long-term Efficacy of Nebivolol After Withdrawal of Therapy

NCT00785512
View directory record Official record
Conditions
Hypertension
Interventions
Nebivolol, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 79 Years
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
26
States / cities
Chandler, Arizona • Phoenix, Arizona • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2010 · Synced Sep 24, 2026, 5:54 PM EDT
Completed Phase 2 Interventional

A Pilot Study Comparing Nebivolol and Atenolol and Its Effects With Exercise in Patients With Mild to Moderate Hypertension

NCT00200421
View directory record Official record
Conditions
Hypertension
Interventions
Nebivolol and Atenolol
Drug
Lead sponsor
Mylan Bertek Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Dec 15, 2005 · Synced Sep 24, 2026, 5:54 PM EDT
Completed Early Phase 1 Interventional

Regression of Myocardial Steatosis by Nebivolol

NCT01358409
View directory record Official record
Conditions
Cardiac Steatosis and Lipotoxicity
Interventions
Nebivolol
Drug
Lead sponsor
Lidia Szczepaniak
Other
Eligibility
18 Years to 59 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 13, 2017 · Synced Sep 24, 2026, 5:54 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Dose Response and Receptor Selectivity of Beta-blocker Effects on Bone Metabolism

NCT02467400
View directory record Official record
Conditions
Osteoporosis, Age-Related
Interventions
Atenolol, Nebivolol, Propranolol, placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
50 Years to 70 Years · Female only
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 5, 2019 · Synced Sep 24, 2026, 5:54 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of the Long-term Safety and Tolerability of Metoprolol Versus Nebivolol in Patients With Hypertension

NCT00142584
View directory record Official record
Conditions
Hypertension
Interventions
Nebivolol (NEB), Metoprolol (MET)
Drug
Lead sponsor
Mylan Bertek Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Mar 14, 2022 · Synced Sep 24, 2026, 5:54 PM EDT
Completed Phase 4 Interventional Results available

Effect of Nebivolol on Oxidative Stress and Endothelial Progenitor Cells

NCT01041287
View directory record Official record
Conditions
Hypertension
Interventions
Nebivolol, Metoprolol succinate
Drug
Lead sponsor
Emory University
Other
Eligibility
21 Years to 80 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 18, 2014 · Synced Sep 24, 2026, 5:54 PM EDT
Withdrawn Phase 2Phase 3 Interventional

Safety Study of Nebivolol for COPD Patients

NCT01939990
View directory record Official record
Conditions
High Blood Pressure
Interventions
Placebo, Nebivolol
Drug
Lead sponsor
University of Chicago
Other
Eligibility
40 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 11, 2016 · Synced Sep 24, 2026, 5:54 PM EDT
Terminated Phase 4 Interventional Results available

Can Nebivolol Reverse Inappropriate Left Ventricular Mass in Hypertensive Patients?

NCT01605370
View directory record Official record
Conditions
Hypertension
Interventions
Nebivolol, Metoprolol succinate
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
30 Years to 70 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated May 18, 2014 · Synced Sep 24, 2026, 5:54 PM EDT
Completed Phase 4 Interventional Results available

Nebivolol Versus Metoprolol: Sodium Sensitivity

NCT00992056
View directory record Official record
Conditions
Hypertension
Interventions
nebivolol, Metoprolol
Drug
Lead sponsor
University of Miami
Other
Eligibility
46 Years and older · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 7, 2017 · Synced Sep 24, 2026, 5:54 PM EDT
Withdrawn Not applicable Interventional

Impact of Nebivolol on Central Aortic Pressure

NCT01051947
View directory record Official record
Conditions
Central Aortic Pressure
Interventions
Nebivolol, Metoprolol
Drug
Lead sponsor
Creighton University
Other
Eligibility
45 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jul 31, 2011 · Synced Sep 24, 2026, 5:54 PM EDT
Terminated Not applicable Interventional Results available

The Impact of Nebivolol Versus Metoprolol on Quality of Life

NCT01441570
View directory record Official record
Conditions
Transplant; Failure, Kidney, Hypertension
Interventions
Nebivolol, Metoprolol succinate
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Boston, Massachusetts • Burlington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 19, 2017 · Synced Sep 24, 2026, 5:54 PM EDT
Completed Phase 2 Interventional Results available

A Study Examining the Effects of Nebivolol Compared to Atenolol on Endothelial Function

NCT01522950
View directory record Official record
Conditions
Hypertension
Interventions
Nebivolol, atenolol, placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 80 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 16, 2020 · Synced Sep 24, 2026, 5:54 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Nebivolol and the Endothelin (ET)-1 System

NCT01395329
View directory record Official record
Conditions
Prehypertension, Hypertension
Interventions
Nebivolol, Metoprolol, Placebo, Forearm Blood Flow (FBF) response to BQ-123 (100 mol/min), FBF response to BQ-123 (100 nmol/min)+BQ-788(50 nmol/min), FBF response to Acetylcholine, FBF response to Sodium Nitroprusside, FBF response to BQ-123+BQ-788+ACh
Drug · Other
Lead sponsor
University of Colorado, Boulder
Other
Eligibility
45 Years to 65 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Boulder, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 1, 2019 · Synced Sep 24, 2026, 5:54 PM EDT
Completed Phase 4 Interventional Results available

Effect of Nebivolol on the Blood Flow in Hearts of Adults With High Blood Pressure and Abnormal Filling of Heart

NCT01961323
View directory record Official record
Conditions
Hypertension, Left Ventricular Diastolic Dysfunction
Interventions
Nebivolol
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 23, 2017 · Synced Sep 24, 2026, 5:54 PM EDT
Completed Phase 3 Interventional

Study of the Efficacy and Safety of the Combination of Two FDA Approved Oral Medications, Nebivolol and Valsartan for Treatment of Stage 1 or 2 Hypertension

NCT01508026
View directory record Official record
Conditions
Stage 1 Hypertension, Stage 2 Hypertension
Interventions
Nebivolol and Valsartan 1, Nebivolol and Valsartan 2, Nebivolol and Valsartan 3, Nebivolol 1, Nebivolol 2, Valsartan 1, Valsartan 2, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
4,161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
413
States / cities
Birmingham, Alabama • Foley, Alabama • Gulf Shores, Alabama + 290 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2014 · Synced Sep 24, 2026, 5:54 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effects of Nebivolol on Skeletal Muscle During Exercise in Hypertensive Patients

NCT01501929
View directory record Official record
Conditions
Hypertension
Interventions
Metoprolol succinate, Nebivolol, Non-invasive measurement of Cardiac Output (CO), Endothelial cell collection, Microvascular perfusion assessment using Definity
Drug · Procedure
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 5, 2018 · Synced Sep 24, 2026, 5:54 PM EDT